Clinical trials: MSA-C
Multiple System Atrophy (MSA)
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
The purpose of this expanded access program is to provide access to the investigational drug verdiperstat in patients with Multiple System Atrophy (MSA).
- Trial name
- NCT05086094
- Testing
- BHV3241, verdiperstat
- Where
- United States
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Leukemia
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
The goal of this clinical research study is to learn if intensive chemotherapy, combined with imatinib mesylate (Gleevec, STI571) given for 8 courses over 6 months, followed by maintenance imatinib mesylate plus chemotherapy for…
- Trial name
- NCT00038610
- Testing
- Imatinib Mesylate, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
CNS Lymphoma
High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study
The purpose of this study is to evaluate the complete response (CR) rate after HD-MTX induction chemotherapy followed by alternative HD MTX-based and HD Cytarabine-based combination consolidation chemotherapy
- Trial name
- NCT01083342
- Testing
- MTX, MVD, VIA
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
PSP, PSP - Progressive Supranuclear Palsy
The CurePSP Genetics Program
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT06647641
- Testing
- Whole genome sequencing will be performed at the NIH
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for…
- Trial name
- NCT06890377
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Min Zhao,MD
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Open Pilot Trial of BHV-4157
24 adults, between the ages of 18 and 75 years, with cerebellar ataxia will be enrolled in a 12 week trial of BHV-4157 for treatment of ataxia.
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia 3
- Trial name
- NCT03408080
- Testing
- BHV-4157
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Los Angeles
Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
TSPO PET in the Evaluation of Neuroinflammation in Patients with Multiple System Atrophy
The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA patients, and to assess its value as a biomarker for diagnostic typing…
- Trial name
- NCT06890390
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Min Zhao,MD
Multiple System Atrophy - Cerebellar Subtype (MSA-C)
The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study.
- Trial name
- SPRITE-C (NCT07514923)
- Testing
- ALT001
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- yilong Wang
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy - Cerebellar Subtype (MSA-C)
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
Multiple system atrophy (MSA) is a disorder of the nervous system of unclear cause. In MSA there is degeneration (progressive loss) of nerve cells in several brain and spinal cord regions.
- Trial name
- NCT02035761
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Lymphoma
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
The goal of this clinical research study is to learn if treatment with two types of chemotherapy combinations can help to control peripheral T-cell lymphoma.
- Trial name
- NCT00290433
- Testing
- Cyclophosphamide, Mesna, Vincristine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple System Atrophy
Lithium in Multiple System Atrophy
The purpose of this study is to determine safety and tolerability of the treatment with lithium in Multiple System Atrophy. Moreover, clinical symptoms, neuronal loss, quality of life and depressive symptoms, will be considered…
- Trial name
- LAMU (NCT00997672)
- Testing
- Lithium Carbonate
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Federico II University
Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant
This is a double-blind, randomized, sham-controlled clinical trial that aim to verify the safety and the efficacy of anodal transcranial direct current stimulation (tDCS) cerebellar symptoms in Multiple System Atrophy type C…
- Trial name
- STIM-MSA (NCT06821256)
- Testing
- Anodal transcranial direct current stimulation (a-tDCS)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Salerno
Spinocerebellar Ataxia Type 3, Multiple System Atrophy-cerebellar Type
Treatment of Transcranial Alternating Current Stimulation（tACS）on Cerebellar Ataxia
This is a longitudinal, triple-blind, randomized-controlled, prospective interventional study assessing patients with cerebellar ataxia, including spinocerebellar ataxia type 3 (SCA3) and multiple system atrophy-cerebellar type…
- Trial name
- NCT05557786
- Testing
- Transcranial Alternating Current Stimulation
- Where
- China
- Volunteers
- 164 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University